OBJECTIVE: To compare the effects of vasopressin versus norepinephrine infusion on the outcome of kidney injury in septic shock. DESIGN AND SETTING: Post-hoc analysis of the multi-center double-blind randomized controlled trial of vasopressin versus norepinephrine in adult patients who had septic shock (VASST). PATIENTS AND INTERVENTION: Seven hundredseventy-eight patients were randomized to receive a blinded infusion of either low-dose vasopressin (0.01-0.03 U/min) or norepinephrine infusion (5-15 microg/min) in addition to open-label vasopressors and were included in the outcome analysis. All vasopressors were titrated and weaned to maintain a target blood pressure. MEASUREMENT AND RESULTS: RIFLE criteria for acute kidney injury were used to compare the effects of vasopressin versus norepinephrine. In view of multiple simultaneous comparisons, a p value of 0.01 was considered statistically significant. Kidney injury was present in 464 patients (59.6%) at study entry. In patients in the RIFLE "Risk" category (n = 106), vasopressin as compared with norepinephrine was associated with a trend to a lower rate of progression to renal "Failure" or "Loss" categories (20.8 vs. 39.6%, respectively, p = 0.03), and a lower rate of use of renal replacement therapy (17.0 vs. 37.7%, p = 0.02). Mortality rates in the "Risk" category patients treated with vasopressin compared to norepinephrine were 30.8 versus 54.7%, p = 0.01, but this did not reach significance in a multiple logistic regression analysis (OR = 0.33, 99% CI 0.10-1.09, p = 0.02). The interaction of treatment group and RIFLE category was significant in predicting mortality. CONCLUSIONS:Vasopressin may reduce progression to renal failure and mortality in patients at risk of kidney injury who have septic shock.
RCT Entities:
OBJECTIVE: To compare the effects of vasopressin versus norepinephrine infusion on the outcome of kidney injury in septic shock. DESIGN AND SETTING: Post-hoc analysis of the multi-center double-blind randomized controlled trial of vasopressin versus norepinephrine in adult patients who had septic shock (VASST). PATIENTS AND INTERVENTION: Seven hundred seventy-eight patients were randomized to receive a blinded infusion of either low-dose vasopressin (0.01-0.03 U/min) or norepinephrine infusion (5-15 microg/min) in addition to open-label vasopressors and were included in the outcome analysis. All vasopressors were titrated and weaned to maintain a target blood pressure. MEASUREMENT AND RESULTS: RIFLE criteria for acute kidney injury were used to compare the effects of vasopressin versus norepinephrine. In view of multiple simultaneous comparisons, a p value of 0.01 was considered statistically significant. Kidney injury was present in 464 patients (59.6%) at study entry. In patients in the RIFLE "Risk" category (n = 106), vasopressin as compared with norepinephrine was associated with a trend to a lower rate of progression to renal "Failure" or "Loss" categories (20.8 vs. 39.6%, respectively, p = 0.03), and a lower rate of use of renal replacement therapy (17.0 vs. 37.7%, p = 0.02). Mortality rates in the "Risk" category patients treated with vasopressin compared to norepinephrine were 30.8 versus 54.7%, p = 0.01, but this did not reach significance in a multiple logistic regression analysis (OR = 0.33, 99% CI 0.10-1.09, p = 0.02). The interaction of treatment group and RIFLE category was significant in predicting mortality. CONCLUSIONS:Vasopressin may reduce progression to renal failure and mortality in patients at risk of kidney injury who have septic shock.
Authors: José António Lopes; Sofia Jorge; Fernando C Neves; Manuel Caneira; António Gomes da Costa; Acácio Cordeiro Ferreira; Mateus Martins Prata Journal: Nephrol Dial Transplant Date: 2006-07-31 Impact factor: 5.992
Authors: Eric A J Hoste; Norbert H Lameire; Raymond C Vanholder; Dominique D Benoit; Johan M A Decruyenaere; Francis A Colardyn Journal: J Am Soc Nephrol Date: 2003-04 Impact factor: 10.121
Authors: Annika Ahlström; Anne Kuitunen; Seija Peltonen; Marja Hynninen; Minna Tallgren; Janne Aaltonen; Ville Pettilä Journal: Am J Kidney Dis Date: 2006-08 Impact factor: 8.860
Authors: Paul M Palevsky; Jane Hongyuan Zhang; Theresa Z O'Connor; Glenn M Chertow; Susan T Crowley; Devasmita Choudhury; Kevin Finkel; John A Kellum; Emil Paganini; Roland M H Schein; Mark W Smith; Kathleen M Swanson; B Taylor Thompson; Anitha Vijayan; Suzanne Watnick; Robert A Star; Peter Peduzzi Journal: N Engl J Med Date: 2008-05-20 Impact factor: 91.245
Authors: James A Russell; Keith R Walley; Joel Singer; Anthony C Gordon; Paul C Hébert; D James Cooper; Cheryl L Holmes; Sangeeta Mehta; John T Granton; Michelle M Storms; Deborah J Cook; Jeffrey J Presneill; Dieter Ayers Journal: N Engl J Med Date: 2008-02-28 Impact factor: 91.245
Authors: Hendrik Bracht; Enrico Calzia; Michael Georgieff; Joel Singer; Peter Radermacher; James A Russell Journal: Br J Pharmacol Date: 2012-04 Impact factor: 8.739
Authors: M Bernhard; G Marx; K Weismüller; C Lichtenstern; K Mayer; F M Brunkhorst; M A Weigand Journal: Anaesthesist Date: 2010-05 Impact factor: 1.041
Authors: Daniel De Backer; Maurizio Cecconi; Jeffrey Lipman; Flavia Machado; Sheila Nainan Myatra; Marlies Ostermann; Anders Perner; Jean-Louis Teboul; Jean-Louis Vincent; Keith R Walley Journal: Intensive Care Med Date: 2019-02-11 Impact factor: 17.440
Authors: Gary Duclos; Michel Cantaloube; Sophie Medam; Noémie Resseguier; Marc Leone Journal: Intensive Care Med Date: 2019-02-06 Impact factor: 17.440